This article is more than 5 years old. Information may no longer be current.

VIDEO: Abicipar pegol inflammation reduced in MAPLE study

ByRaj K Maturi, MD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — At the American Society of Retina Specialists meeting, Raj K. Maturi, MD, discusses the results of the MAPLE study of abicipar pegol (Allergan), showing that intraocular inflammation was half the amount as had occurred in the phase 3 studies of the drug due to a new manufacturing process.